US2019030141A1PendingUtilityA1
Compositions and methods for treating fungal and bacterial pathogens
Assignee: LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CTPriority: Mar 15, 2013Filed: Oct 11, 2018Published: Jan 31, 2019
Est. expiryMar 15, 2033(~6.7 yrs left)· nominal 20-yr term from priority
A61K 39/0002A61K 39/104A61P 31/04A61P 31/10C07K 14/40C07K 14/212C07K 16/14A61K 2039/55505C07K 2319/00C07K 2317/76A61K 2039/54A61K 39/39C12R 2001/725C12N 1/165
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention features fragments of the Candida cell surface proteins Als3 and Hyr1 and combinations thereof useful in immunizing a subject against fungal or bacterial infections or both.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An isolated polypeptide optionally fused to a heterologous fusion partner, wherein the amino acid sequence of said polypeptide consists of an amino acid sequence having at least 95% identity to
Als (18-324)
(SEQ ID NO: 2)
KTI TGVFNSFNSLTWSNAATYNY KGPGTPTWNAVLGWSLDGTS
ASPGDTFTLNMPCVFKFTTS QTSVDLTAHGVKYATCQFQA GEEFMTFSTLTCTVSNTLTP
SIKALGTVTLPLAFNVGGTG SSVDLEDSKCFTAGTNTVTF NDGGKKISINVDFERSNVDP
KGYLTDSRVIPSLNKVSTLF VAPQCANGYTSGTMGFANTY GDVQIDCSNIHVGITKGLND
WNYPVSSESFSYTKTCSSNG IFITYKNVPAGYRPFVDAYI SATDVNSYTLSYANEYTCAG
GYWQRAPFTLRWTGYRNSDA GSNG.
2 . An isolated polypeptide optionally fused to a heterologous fusion partner, wherein the amino acid sequence of said polypeptide consists of an amino acid sequence having at least 95% identity to
Als3 (Ser/Thr-rich sequence)
(SEQ ID NO: 3)
IVIVATTRTVTDSTTA VTTLPFDPNRDKTKTIEILK
PIPTTTITTSYVGVTTSYST KTAPIGETATVIVDIPYHTT TTVTSKWTGTITSTTTHTNP
TDSIDTVIVQVP.
3 . An isolated polypeptide optionally fused to a heterologous fusion partner, wherein the amino acid sequence of said polypeptide consists of an amino acid sequence having at least 95% identity to
Hyr1 (hydrophobic sequence)
(SEQ ID NO: 5)
TSRIDRGGIQGFHGDVKVHS GATWAILGTTLCSFFGGLEV EKGASLFIKSDNGPVLALNV
ALSTLVRPVINNGVISLNSK SSTSFSNFDIGGSSFTNNGE IYLDSSGLVKSTAYLYAREW
TNNGLIVAY.
4 . An isolated polypeptide optionally fused to a heterologous fusion partner, wherein the amino acid sequence of said polypeptide consists of an amino acid sequence having at least 95% identity to
Hyr1 (154-350)
(SEQ ID NO: 6)
QNQKAAG NIAFGTAYQTITNNGQICLR
HQDFVPATKIKGTGCVTADE DTWIKLGNTILSVEPTHNFY LKDSKSSLIVHAVSSNQTFT
VHCFGNGNKLGLTLPLTGNR DHFRFEYYPDTGILQLRADA LPQYFKIGKGYDSKLFRIVN
SRGLKNAVTYDGPVPNNEIP AVCLIPCTNGPSAPESESDL NTPTTSSIET.
5 . An isolated polypeptide optionally fused to a heterologous fusion partner, wherein the amino acid sequence of said polypeptide consists of an amino acid sequence having at least 95% identity to
Hyr1 (201-350)
(SEQ ID NO: 7)
DTWIKLGNTILSVEPTHNFY LKDSKSSLIVHAVSSNQTFT
VHGFGNGNKLGLTLPLTGNR DHFRFEYYPDTGILQLRADA LPQYFKIGKGYDSKLFRIVN
SRGLKNAVTYDGPVPNNEIP AVCLIPCINGPSAPESESDL NTPTTSSIET.
6 . An isolated polypeptide optionally fused to a heterologous fusion partner, wherein the amino acid sequence of said polypeptide consists of an amino acid sequence having at least 95% identity to
Hyr1 (25-469)
(SEQ ID NO: 8)
TSRIDRGGIQGFHGDV KVHSGATWAILGTTLCSFFG
GLEVEKGASLFIKSDNGPVL ALNVALSTLVRPVINNGVIS LNSKSSTSFSNFDIGGSSFT
NNCEIYLDSSGLVKSTAYLY AREWTNNCLIVAYQNQKAAC NIAFCTAYQTITNNGQICLR
HQDFVPATKIKGTGCVTADE DTWIKLGNTILSVEPTHNFY LKDSKSSLIVHAVSSNQTFT
VHGFGNGNKLGLTLPLTGNR DHFRFEYYPDTGILQLRADA LPQYFKIGKGYDSKLFRIVN
SRGLKNAVTYDGPVPNNEIP AVCLIPCTNGPSAPESESDL NTPTTSSIETSSYSSAATES
SVVSESSSAVDSLTSSSLSS KSESSDVVSSTTNIESSSTA IETTMNSESSTDAGSSSISQ
SESSSTAITSSSETSSSESM SASSTTASNTSIETDSGIVS QSESSSNAL.
7 . An isolated polypeptide optionally fused to a heterologous fusion partner, wherein the amino acid sequence of said polypeptide consists of an amino acid sequence having at least 95% identity to
Hyr1 (201-469)
(SEQ ID NO: 9)
DTWIKLGNTILSVEPTHNFY LKDSKSSLIVHAVSSNQTFT
VHGFGNGNKLGLTLPLTGNR DHFRFEYYPDTGILQLRADA LPQYFKIGKGYDSKLFRIVN
SRGLKNAVTYDGPVPNNEIP AVCLIPCINGPSAPESESDL NTPTTSSIETSSYSSAATES
SVVSESSSAVDSLTSSSLSS KSESSDVVSSTTNIESSSTA IETTMNSESSTDAGSSSISQ
SESSSTAITSSSETSSSESM SASSTTASNTSIETDSGIVS QSESSSNAL.
8 . An isolated polypeptide optionally fused to a heterologous fusion partner, wherein the amino acid sequence of said polypeptide consists of an amino acid sequence having at least 95% identity to
Hyr1 (Ser/Thr-rich sequence)
(SEQ ID NO: 10)
SSYSSAATESSVVS ESSSAVDSLTSSSLSSKSES
SDVVSSTTNIESSSTAIETT MNSESSTDAGSSSISQSESS STAITSSSETSSSESMSASS
TTASNTSIETDSGIVSQSES SSNAL.
9 . An isolated polypeptide optionally fused to a heterologous fusion partner, wherein the amino acid sequence of said polypeptide consists of an amino acid sequence having at least 95% identity to
Hyr1 (154-469)
(SEQ ID NO: 33)
QNQKAAG NIAFGTAYQTITNNGQICLR
HQDFVPATKIKGTGCVTADE DTWIKLCNTILSVEPTHNFY LKDSKSSLIVHAVSSNQTFT
VHGFGNGNKLGLTLPLTGNR DHERFEYYPDTGILQLRADA LPQYFKIGKGYDSKLFRIVN
SRGLKNAVTYDGPVPNNEIP AVCLIPCTNGPSAPESESDL NTPTTSSIETSSYSSAATES
SVVSESSSAVDSLTSSSLSS KSESSDVVSSTTNIESSSTA IETTMNSESSTDACSSSISQ
SESSSTAITSSSEISSSESM SASSTTASNTSIETDSGIVS QSESSSNAL.
10 . An isolated polypeptide comprising a sequence having substantial identity to the amino acid sequence
E. coli expressed Als3/Hyr1 fusion proteins
E1=A-B-X-C-D
A-B-X-C-D (SEQ ID NO: 11),
wherein A is SEQ ID NO: 2;
wherein B is SEQ ID NO: 3;
wherein X is absent or is a linker peptide;
wherein C is SEQ ID NO: 5; and
wherein D is SEQ ID NO: 6.
11 . The isolated polypeptide of claim 10 , wherein said polypeptide is substantially identical to A-B-C-D (SEQ ID NO: 12).
12 . The isolated polypeptide of claim 10 , wherein said polypeptide is A-B-C-D (SEQ ID NO: 12).
13 . An isolated polypeptide comprising a sequence having substantial identity to the amino acid sequence
E2=A-X-C-D
A-X-C-D (SEQ ID NO: 13),
wherein A is SEQ ID NO: 2;
wherein X is absent or is a linker peptide;
wherein C is SEQ ID NO: 5; and
wherein D is SEQ ID NO: 6.
14 . The isolated polypeptide of claim 13 , wherein said polypeptide is substantially identical to A-C-D (SEQ ID NO: 14).
15 . The isolated polypeptide of claim 13 , wherein said polypeptide is A-C-D (SEQ ID NO: 14).
16 . An isolated polypeptide comprising a sequence having substantial identity to the amino acid sequence
E3=A-X-D
A-X-D (SEQ ID NO: 15),
wherein A is SEQ ID NO: 2;
wherein X is absent or is a linker peptide; and
wherein D is SEQ ID NO: 6.
17 . The isolated polypeptide of claim 16 , wherein said polypeptide is substantially identical to A-D (SEQ ID NO: 16).
18 . The isolated polypeptide of claim 16 , wherein said polypeptide is A-D (SEQ ID NO: 16).
19 . An isolated polypeptide comprising a sequence having substantial identity to the amino acid sequence
E4=C-D-X-A-B
C-D-X-A-B (SEQ ID NO: 17),
wherein C is SEQ ID NO: 5;
wherein D is SEQ ID NO: 6;
wherein X is absent or is a linker peptide;
wherein A is SEQ ID NO: 2; and
wherein B is SEQ ID NO: 3.
20 . The isolated polypeptide of claim 19 , wherein said polypeptide is substantially identical to C-D-A-B (SEQ ID NO: 18).
21 . The isolated polypeptide of claim 19 , wherein said polypeptide is C-D-A-B (SEQ ID NO: 18).
22 . An isolated polypeptide comprising a sequence having substantial identity to the amino acid sequence
E5=C-D-X-A
C-D-X-A (SEQ ID NO: 19),
wherein C is SEQ ID NO: 5;
wherein D is SEQ ID NO: 6;
wherein X is absent or is a linker peptide; and
wherein A is SEQ ID NO: 2.
23 . The isolated polypeptide of claim 22 , wherein said polypeptide is substantially identical to C-D-A (SEQ ID NO: 20).
24 . The isolated polypeptide of claim 22 , wherein said polypeptide is C-D-A (SEQ ID NO: 20).
25 . An isolated polypeptide comprising a sequence having substantial identity to the amino acid sequence
E6=D-X-A-B
D-X-A-B (SEQ ID NO: 21),
wherein D is SEQ ID NO: 6;
wherein X is absent or is a linker peptide;
wherein A is SEQ ID NO: 2; and
wherein B is SEQ ID NO: 3.
26 . The isolated polypeptide of claim 25 , wherein said polypeptide is substantially identical to D-A-B (SEQ ID NO: 22).
27 . The isolated polypeptide of claim 25 , wherein said polypeptide is D-A-B (SEQ ID NO: 22).
28 . An isolated polypeptide comprising a sequence having substantial identity to the amino acid sequence
E7 D-X-A
D-X-A (SEQ ID NO: 23),
wherein D is SEQ ID NO: 6;
wherein X is absent or is a linker peptide; and
wherein A is SEQ ID NO: 2.
29 . The isolated polypeptide of claim 28 , wherein said polypeptide is substantially identical to D-A (SEQ ID NO: 24).
30 . The isolated polypeptide of claim 28 , wherein said polypeptide is D-A (SEQ ID NO: 24).
31 . An isolated polypeptide comprising a sequence having substantial identity to the amino acid sequence
S. cerevisiae expressed Als3/Hyr1 fusion proteins
S1=A-B-X-C-D
A-B-X-C-D (SEQ ID NO: 11),
wherein A is SEQ ID NO: 2;
wherein B is SEQ ID NO: 3;
wherein X is absent or is a linker peptide;
wherein C is SEQ ID NO: 5; and
wherein D is SEQ ID NO: 6.
32 . The isolated polypeptide of claim 31 , wherein said polypeptide is substantially identical to A-B-C-D (SEQ ID NO: 12).
33 . The isolated polypeptide of claim 31 , wherein said polypeptide is A-B-C-D (SEQ ID NO: 12).
34 . An isolated polypeptide comprising a sequence having substantial identity to the amino acid sequence
S2=A-X-C-D-E
A-X-C-D-E (SEQ ID NO: 25),
wherein A is SEQ ID NO: 2;
wherein X is absent or is a linker peptide;
wherein C is SEQ ID NO: 5;
wherein D is SEQ ID NO: 6; and
wherein E is SEQ ID NO: 10.
35 . The isolated polypeptide of claim 34 , wherein said polypeptide is substantially identical to A-C-D-E (SEQ ID NO: 26).
36 . The isolated polypeptide of claim 34 , wherein said polypeptide is A-C-D-E (SEQ ID NO: 26).
37 . An isolated polypeptide comprising a sequence having substantial identity to the amino acid sequence
S3=A-X-D-E
A-X-D-E (SEQ ID NO: 27),
wherein A is SEQ ID NO: 2;
wherein X is absent or is a linker peptide;
wherein D is SEQ ID NO: 6; and
wherein E is SEQ ID NO: 10.
38 . The isolated polypeptide of claim 37 , wherein said polypeptide is substantially identical to A-D-E (SEQ ID NO: 28).
39 . The isolated polypeptide of claim 37 , wherein said polypeptide is A-D-E (SEQ ID NO: 28).
40 . An isolated polypeptide comprising a sequence having substantial identity to the amino acid sequence
S4=C-D-E-X-A-B
C-D-E-X-A-B (SEQ ID NO: 29),
wherein C is SEQ ID NO: 5;
wherein D is SEQ ID NO: 6;
wherein E is SEQ ID NO: 10;
wherein X is absent or is a linker peptide;
wherein A is SEQ ID NO: 2; and
wherein B is SEQ ID NO: 3.
41 . The isolated polypeptide of claim 40 , wherein said polypeptide is substantially identical to C-D-E-A-B (SEQ ID NO: 30).
42 . The isolated polypeptide of claim 40 , wherein said polypeptide is C-D-E-A-B (SEQ ID NO: 30).
43 . An isolated polypeptide comprising a sequence having substantial identity to the amino acid sequence
S5=C-D-X-A-B
C-D-X-A-B (SEQ ID NO: 17),
wherein C is SEQ ID NO: 5;
wherein D is SEQ ID NO: 6;
wherein X is absent or is a linker peptide;
wherein A is SEQ ID NO: 2; and
wherein B is SEQ ID NO: 3.
44 . The isolated polypeptide of claim 43 , wherein said polypeptide is substantially identical to C-D-A-B (SEQ ID NO: 18).
45 . The isolated polypeptide of claim 43 , wherein said polypeptide is C-D-A-B (SEQ ID NO: 18).
46 . An isolated polypeptide comprising a sequence having substantial identity to the amino acid sequence
S6=D-X-A-B
D-X-A-B (SEQ ID NO: 21),
wherein D is SEQ ID NO: 6;
wherein X is absent or is a linker peptide;
wherein A is SEQ ID NO: 2; and
wherein B is SEQ ID NO: 3.
47 . The isolated polypeptide of claim 46 , wherein said polypeptide is substantially identical to D-A-B (SEQ ID NO: 22).
48 . The isolated polypeptide of claim 46 , wherein said polypeptide is D-A-B (SEQ ID NO: 22).
49 . An isolated polypeptide comprising a sequence having substantial identity to the amino acid sequence
S7=D-X-A
D-X-A (SEQ ID NO: 23),
wherein D is SEQ ID NO: 6;
wherein X is absent or is a linker peptide; and
wherein A is SEQ ID NO: 2.
50 . The isolated polypeptide of claim 49 , wherein said polypeptide is substantially identical to D-A (SEQ ID NO: 24).
51 . The isolated polypeptide of claim 49 , wherein said polypeptide is D-A (SEQ ID NO: 24).
52 . An isolated nucleic acid molecule which encodes a polypeptide of any one of claim 1 - 51 , 59 , or 118 - 137 .
53 . An isolated nucleic acid molecule comprising a nucleic acid sequence which is substantially identical to the isolated nucleic acid molecule of claim 52 .
54 . A vector comprising the nucleic acid molecule of claim 52 or 53 .
55 . A cell comprising the nucleic acid molecule of claim 52 or 53 .
56 . A method of producing a recombinant polypeptide, said method comprising the steps of:
(a) providing a cell transformed with the nucleic acid molecule of claim 52 or 53 encoding an polypeptide positioned for expression in the cell; (b) culturing the transformed cell under conditions for expressing the nucleic acid molecule, wherein said culturing results in expression of said recombinant polypeptide; and (c) isolating the recombinant polypeptide.
57 . The method of claim 56 , wherein said cell is a bacterium.
58 . The method of claim 57 , wherein said cell is a yeast.
59 . A recombinant polypeptide produced according to the method of claim 56 .
60 . A substantially pure antibody that specifically recognizes and binds to any one of the polypeptides of claim 1 - 51 , 59 , or 118 - 137 .
61 . An antigenic composition comprising the polypeptide of any one of claim 1 - 51 , 59 , or 118 - 137 , and a pharmaceutically acceptable carrier, diluent, and/or excipient.
62 . The composition of claim 61 , further comprising an adjuvant.
63 . A method of inducing an immune response in a mammal against an antigen comprising administering a polypeptide of any one of claim 1 - 51 , 59 , or 118 - 137 , or the antigenic composition of claim 61 to said mammal, wherein said polypeptide or said composition induces an immune response against said antigen in said mammal.
64 . The method of claim 63 , wherein the mammal is administered a single dose of said polypeptide or said composition.
65 . The method of claim 63 , wherein the mammal is administered a plurality of doses of said polypeptide or said composition.
66 . The method of claim 63 , wherein said plurality of doses are administered at least one day apart.
67 . The method of claim 65 , wherein said composition is administered twice.
68 . The method of claim 65 , wherein said plurality of doses are administered at least two weeks apart.
69 . The method of any one of claims 63 - 68 , wherein said mammal is a human.
70 . A vaccine comprising an immunogenic amount of the polypeptide of any one of claim 1 - 51 , 59 , or 118 - 137 , and a pharmaceutically acceptable excipient.
71 . The vaccine of claim 70 , comprising a mixture of distinct polypeptides of any one of claim 1 - 51 , 59 , or 118 - 137 .
72 . The vaccine of claim 70 or 71 , further comprising an adjuvant.
73 . The vaccine of claim 72 , wherein said adjuvant is Alhydrogel.
74 . The vaccine of any one of claims 70 - 73 for use in the vaccination of a mammal against candidiasis or a gram negative bacterium or S. aureus.
75 . The vaccine of claim 74 , wherein said mammal is a human.
76 . The vaccine of claim 74 or 75 , wherein said vaccine is to be administered by intramuscular, subcutaneous, or intradermal administration.
77 . The vaccine of claim 76 , wherein said vaccine is to be administered by intramuscular administration.
78 . The vaccine of any one of claims 70 - 77 , wherein said vaccination further comprises administering a booster dose.
79 . The vaccine of any one of claims 74 - 77 , wherein said candidiasis is disseminated candidiasis.
80 . The vaccine of claim 79 , wherein said disseminated candidiasis is hematogenously disseminated candidiasis.
81 . The vaccine of any one of claims 74 - 77 , wherein said candidiasis is mucosal candidiasis.
82 . The vaccine of any one of claims 74 - 81 , wherein said candidiasis is caused by Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis , or Candida tropicalis.
83 . A method of vaccinating a mammal against candidiasis comprising administering to said mammal the vaccine of claim 70 , thereby vaccinating said mammal against candidiasis or a gram negative bacterium or S. aureus.
84 . The method of claim 83 , wherein said mammal is a human.
85 . The method of claim 83 or 84 , wherein said vaccine is administered by intramuscular, subcutaneous, or intradermal administration.
86 . The method of claim 83 or 84 , wherein said vaccine is administered by intramuscular administration.
87 . The method of any one of claims 83 - 86 , wherein said administering further comprises administering a booster dose.
88 . The method of any one of claims 83 - 87 , wherein said candidiasis is disseminated candidiasis.
89 . The method of claim 88 , wherein said disseminated candidiasis is hematogenously disseminated candidiasis.
90 . The method of any one of claims 83 - 87 , wherein said candidiasis is mucosal candidiasis.
91 . The method of any one of claims 83 - 90 , wherein said candidiasis is caused by Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis , or Candida tropicalis.
92 . A method of producing a chimeric vaccine comprising the steps of:
(a) providing a phage, yeast, or virus; (b) inserting into said phage, yeast, or virus a nucleic acid molecule that encodes the polypeptide of any one of claim 1 - 51 , 59 , or 118 - 137 ; (c) allowing expression of said polypeptide in said phage, yeast, or virus; (d) isolating said phage, yeast, or virus of step (c) comprising said expressed polypeptide; and (e) adding a pharmaceutically acceptable excipient to said isolated phage, yeast, or virus of step (d).
93 . The method of claim 92 , wherein said polypeptide is displayed on the surface of said phage, yeast, or virus following step (c).
94 . An isolated monoclonal antibody that binds to the polypeptide of any one of claim 1 - 51 , 59 , or 118 - 137 .
95 . The antibody of claim 94 , wherein said antibody is human or humanized.
96 . The antibody of claim 94 , wherein said antibody is chimeric.
97 . The antibody of any one of claims 94 and 96 , wherein said antibody is produced recombinantly.
98 . A diagnostic composition comprising the antibody of any one of claims 94 - 97 .
99 . A pharmaceutical composition comprising the antibody of any one of claims 94 - 97 and a pharmaceutically acceptable excipient.
100 . The pharmaceutical composition of claim 99 , comprising a mixture of antibodies of any one of claims 94 - 97 with a plurality of distinct specificities.
101 . A pharmaceutical composition comprising polyclonal antibodies that bind to the polypeptide of any one of claim 1 - 51 , 59 , or 118 - 137 , or that bind to a mixture of distinct polypeptides of any one of claim 1 - 51 , 59 , or 118 - 137 .
102 . The pharmaceutical composition of any one of claims 98 - 100 for use in the passive immunization of a mammal against candidiasis or a gram negative bacterium or S. aureus.
103 . The composition of claim 102 , wherein said mammal is a human.
104 . The composition of claim 102 or 103 , wherein said pharmaceutical composition is administered by intramuscular, subcutaneous, or intradermal administration.
105 . The composition of claim 104 , wherein said pharmaceutical composition is administered by intramuscular administration.
106 . The composition of any one of claims 102 - 105 , wherein said candidiasis is disseminated candidiasis.
107 . The composition of claim 106 , wherein said disseminated candidiasis is hematogenously disseminated candidiasis.
108 . The composition of any one of claims 102 - 105 , wherein said candidiasis is mucosal candidiasis.
109 . The composition of any one of claims 102 - 108 , wherein said candidiasis is caused by Candida albicans, Candida glabrata, Candida krusei, Candida parapsiiosis , or Candida tropicalis.
110 . A method of passive immunization of a mammal against candidiasis comprising administering to said mammal an effective amount of the pharmaceutical composition of claim 102 , thereby passively immunizing said mammal against said candidiasis or a gram negative bacterium or S. aureus.
111 . The method of claim 110 , wherein said mammal is a human.
112 . The method of claim 110 or 111 , wherein said pharmaceutical composition is administered by intramuscular, subcutaneous, or intradermal administration.
113 . The method of claim 112 , wherein said pharmaceutical composition is administered by intramuscular administration.
114 . The method of any one of claims 110 - 113 , wherein said candidiasis is disseminated candidiasis.
115 . The method of claim 114 , wherein said disseminated candidiasis is hematogenously disseminated candidiasis.
116 . The method of any one of claims 110 - 113 , wherein said candidiasis is mucosal candidiasis.
117 . The method of any one of claims 110 - 116 , wherein said candidiasis is caused by Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis , or Candida tropicalis.
118 . An isolated polypeptide comprising a sequence having substantial identity to the amino acid sequence
A-B-X-C-D-E (SEQ ID NO: 31),
wherein A is absent or is SEQ ID NO: 2;
wherein B is absent or is SEQ ID NO: 3;
wherein X is absent or is a linker peptide;
wherein C is absent or is SEQ ID NO: 5;
wherein D is absent or is SEQ ID NO: 6; and
wherein E is absent or is SEQ ID NO: 10,
provided that two or more of A, B, C, D and E are present in said polypeptide.
119 . The polypeptide of claim 118 , wherein said polypeptide is A-B-C-D-E (SEQ ID NO: 32).
120 . The polypeptide of claim 118 , wherein said polypeptide is A-B-X-C-D (SEQ ID NO: 11).
121 . The polypeptide of claim 120 , wherein said polypeptide is A-B-C-D (SEQ ID NO: 12).
122 . The polypeptide of claim 118 , wherein said polypeptide is A-X-C-D-E (SEQ ID NO: 25).
123 . The polypeptide of claim 122 , wherein said polypeptide is A-C-D-E (SEQ ID NO: 26).
124 . The polypeptide of claim 118 , wherein said polypeptide is A-X-C-D (SEQ ID NO: 13).
125 . The polypeptide of claim 124 , wherein said polypeptide is A-C-D (SEQ ID NO: 14).
126 . The polypeptide of claim 118 , wherein said polypeptide is A-X-D-E (SEQ ID NO: 27).
127 . The polypeptide of claim 126 , wherein said polypeptide is A-D-E (SEQ ID NO: 28).
128 . The polypeptide of claim 118 , wherein said polypeptide is A-X-D (SEQ ID NO: 15).
129 . The polypeptide of claim 128 , wherein said polypeptide is A-D (SEQ ID NO: 16).
130 . An isolated polypeptide comprising a sequence having substantial identity to the amino acid sequence
C-D-E-X-A-B (SEQ ID NO: 29),
wherein C is absent or is SEQ ID NO: 5;
wherein D is absent or is SEQ ID NO: 6;
wherein E is absent or is SEQ ID NO: 10;
wherein X is absent or is a linker peptide;
wherein A is absent or is SEQ ID NO: 2;
wherein B is absent or is SEQ ID NO: 3,
provided that two or more of C, D, E, A, and B are present in said polypeptide.
131 . The polypeptide of claim 130 , wherein said polypeptide is C-D-E-A-B (SEQ ID NO: 30).
132 . The polypeptide of claim 130 , wherein said polypeptide is C-D-X-A-B (SEQ ID NO: 17).
133 . The polypeptide of claim 132 , wherein said polypeptide is C-D-A-B (SEQ ID NO: 18).
134 . The polypeptide of claim 130 , wherein said polypeptide is D-X-A-B (SEQ ID NO: 21).
135 . The polypeptide of claim 134 , wherein said polypeptide is D-A-B (SEQ ID NO: 22).
136 . The polypeptide of claim 130 , wherein said polypeptide is D-X-A (SEQ ID NO: 23).
137 . The polypeptide of claim 136 , wherein said polypeptide is D-A (SEQ ID NO: 24).
138 . In any aforementioned claim, wherein the gram negative bacterium is Acinetobacter.
139 . In any aforementioned claim, wherein S. aureus is MRSA.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.